MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Gets Positive Review In Seeking Alpha's Equity Stock Guru Article 0 comments
    Nov 1, 2013 2:02 PM | about stocks: CYTR

    Oncological biopharm company CytRx today was featured in a Seeking Alpha article detailing the company's recent flurry of positive news as well as its promising drug candidate pipeline. Access the full article on Seeking Alpha here: seekingalpha.com/article/1797082.

    As recapped in the article, CytRx' lead candidate is aldoxorubicin, the company's improve formulation of the commonly used chemotherapy agent doxorubicin. CytRx is currently pursuing several indications with aldoxorubicin:

    •2nd-Line Soft Tissue Sarcoma (NYSEMKT:STS)

    •1st-Line Soft Tissue Sarcoma

    •Glioblastoma Multiforme (GBM)

    •Kaposi's Sarcoma

    SeekingAlpha contributor Equity Options Guru also noted CytRx' interim results from its phase 2b Trial for aldoxorubicin for 1st-Line Soft Tissue Sarcoma, which demonstrated that patients treated with the drug candidate had a higher overall response rate (22 percent) compared to those treated with doxorubicin (0 percent). The company is expected to release its top-line progression-free survival results in December 2013.

    Among other points of interest, the article outlines four of CytRx' upcoming events:

    •4th Quarter 2013 - CytRx plans to commence a phase 2 trial with aldoxorubicin in patients with relapsed glioblastoma.

    •4th Quarter 2013 - CytRx plans to begin a phase 2 trial evaluating the preliminary efficacy of aldoxorubicin in treating AIDS-related Kaposi's sarcoma.

    •December 2013 - As mentioned above, the company will release top-line progression-free survival results from the phase 2b 1st-Line Soft Tissue Sarcoma trial.

    •1st Quarter 2014 - CytRx will start a phase 3 pivotal trial with aldoxorubicin for 2nd-Line Soft Tissue Sarcoma in patients who have failed chemotherapy.

    In conclusion, Equity Options Guru issues a positive take on the biopharmaceutical company, forecasting near-term growth based on its upcoming catalysts and financial standing.

    "CytRx appears poised for significant growth over the next 6-12 months. The company is developing potential treatments in areas with a major unmet medical need. Should any of those treatments prove to be successful, it is likely that the share price could soar. With 4 major catalysts and a healthy financial position, investors may want to consider taking at least a small position in the company now before it's too late," wrote Equity Options Guru.

    For more information on CytRx, visit cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.